Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist.Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries. Medical uses
In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older. Society and culture
Legal status
Trifarotene was approved for medical use in the United States in October 2019, in Canada in November 2019, and in Australia in January 2021. References
External links
"Trifarotene". Drug Information Portal. U.S. National Library of Medicine (NLM).
(Consecutive exotropia may however also spontaneously develop from esotropia, without surgery or botulinum toxin treatment.) Because of the risks of surgery, and because about 35% of people require at least one more surgery, many people try vision therapy first. This consists of visual exercises. Although vision therapy is generally not covered by American health insurance companies, many large insurers such as Aetna have recently begun offering full or partial coverage in response to recent studies. Strabismus surgery is sometimes recommended if the exotropia is present for more than half of each day or if the frequency is increasing over time. It is also indicated if a child has significant exotropia when reading or viewing near objects or if evidence shows that the eyes are losing their ability to work as a single unit (binocular vision). Finally, if there is a complaint of headaches, and no other cause for the headaches can be found, then these headaches could be because the child or adult is trying to control the exotropia. If none of these criteria are met, surgery may be postponed pending simple observation with or without some form of eyeglass and/or patching therapy. In very mild cases, a chance exists that the exotropia will diminish with time. The long-term success of surgical treatment for conditions such as intermittent exotropia is not well proven, and surgery can often result in a worsening of symptoms due to overcorrection. Evidence from systematic reviews of interventions show clinical benefits for patching for children ages 12 months to ten years.